Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity
Condition: Coronavirus Disease 2019 Intervention: Biological: Recombinant new coronavirus vaccine (CHO cell) group Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials